Jacobs Levy Equity Management Inc. Has $1.31 Million Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Jacobs Levy Equity Management Inc. lessened its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 23.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 390,899 shares of the company's stock after selling 118,572 shares during the period. Jacobs Levy Equity Management Inc. owned 0.46% of Atea Pharmaceuticals worth $1,310,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in Atea Pharmaceuticals by 5.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 73,883 shares of the company's stock valued at $248,000 after buying an additional 3,882 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Atea Pharmaceuticals by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company's stock worth $2,209,000 after acquiring an additional 9,370 shares during the last quarter. Renaissance Technologies LLC increased its position in Atea Pharmaceuticals by 0.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,216,600 shares of the company's stock worth $4,076,000 after acquiring an additional 9,500 shares during the period. Wells Fargo & Company MN raised its stake in Atea Pharmaceuticals by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 45,391 shares of the company's stock valued at $152,000 after purchasing an additional 9,865 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in Atea Pharmaceuticals by 1.9% in the 4th quarter. Federated Hermes Inc. now owns 582,939 shares of the company's stock valued at $1,953,000 after purchasing an additional 10,856 shares during the period. 86.67% of the stock is currently owned by institutional investors.

Atea Pharmaceuticals Stock Performance

Shares of NASDAQ AVIR traded up $0.09 during mid-day trading on Tuesday, hitting $2.90. 369,745 shares of the stock were exchanged, compared to its average volume of 307,296. The stock's fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $3.09. Atea Pharmaceuticals, Inc. has a twelve month low of $2.46 and a twelve month high of $4.15. The company has a market cap of $248.18 million, a P/E ratio of -1.40 and a beta of 0.17.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.16. As a group, equities research analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AVIR. Morgan Stanley dropped their price objective on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. William Blair reaffirmed an "outperform" rating on shares of Atea Pharmaceuticals in a report on Friday, March 7th.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.